Dose-intensified SRT Minimally Impacts Quality of Life in Biochemical Recurrent Prostate Cancer

Share this content:
Dose-intensified salvage radiation therapy was associated with low rates of acute toxicity and minimally impacts quality of life.
Dose-intensified salvage radiation therapy was associated with low rates of acute toxicity and minimally impacts quality of life.

Dose-intensified salvage radiation therapy (SRT) was associated with low rates of acute toxicity and minimally impacts quality of life, except for significantly worsening urinary symptoms, in patients with biochemically recurrent prostate cancer after prostatectomy, a recent study published online ahead of print in the Journal of Clinical Oncology has shown.1

After radical prostatectomy, approximately 15% to 40% of patients experience biochemical failure within 5 years. Current National Comprehensive Cancer Network (NCCN) guidelines for the management of prostate cancer recommend external beam radiation therapy, androgen deprivation therapy, or observation for biochemical failure after prostatectomy in patients with imaging studies negative for distant metastases.2

The only potentially curative treatment option at the earliest detection of biochemical failure is SRT, but though it may be beneficial, it is unclear how this approach will affect gastrointestinal and genitourinary toxicity.

Therefore, researchers sought to evaluate the impact of dose-intensified SRT without androgen-deprivation therapy on acute toxicity and early quality of life in patients with biochemical recurrence after radical prostatectomy.1

For the phase 3 trial, researchers enrolled 350 patients with biochemical failure but without evidence of macroscopic disease.

RELATED: New Model to Identify High-Risk Prostate Cancer May Decrease Unnecessary Biopsies

Participants were randomly assigned to receive either 64 or 70 Gy of radiotherapy therapy using 3-dimensional conformal radiation therapy or intensity-modulated radiotherapy therapy/rotational techniques.

Among the 344 evaluable patients aged 48 to 75 years, 30 patients had grade 2 and 2 patients had grade 3 genitourinary symptoms at baseline, while 1 patient had grade 2 baseline gastrointestinal toxicity.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters